Cargando…
Mesenchymal stem cell therapy for severe COVID-19
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed a global public burden on health authorities. Although the virological characteristics and pathogenesis of COVID-19 has been largely clarified, there is currently no specific t...
Autores principales: | Shi, Lei, Wang, Lifeng, Xu, Ruonan, Zhang, Chao, Xie, Yunbo, Liu, Kai, Li, Tiantian, Hu, Wei, Zhen, Cheng, Wang, Fu-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424619/ https://www.ncbi.nlm.nih.gov/pubmed/34497264 http://dx.doi.org/10.1038/s41392-021-00754-6 |
Ejemplares similares
-
Mesenchymal stem cells, implications for pain therapy
por: Trallori, Elena, et al.
Publicado: (2019) -
Mesenchymal stem cell treatment for COVID-19
por: Xu, Ruonan, et al.
Publicado: (2022) -
Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial
por: Shi, Lei, et al.
Publicado: (2021) -
Advancing mesenchymal stem/stromal cells-based therapies for neurologic disease
por: Phinney, Donald G.
Publicado: (2017) -
Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives
por: Karakaş, Nihal, et al.
Publicado: (2022)